Sedentary Lifestyle Trends Fueling Growth In The Muscle Wasting Disorders Market: The Driving Engine Behind Muscle Wasting Disorders Market Evolution in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Muscle Wasting Disorders Market Size Growth Forecast: What to Expect by 2025?
The domain of muscle wasting disorders has experienced swift expansion lately, projecting an increase in market valuation from $15.06 billion in 2024 up to $17.49 billion a year later, reflecting a robust compound annual growth rate of 16.1% across this past period, a trajectory fueled by several key factors including the expanding demographic of older individuals, the escalating prevalence of long-term illnesses, notable progress in scientific investigation and product creation, heightened recognition surrounding the importance of timely disease identification, and the advent of novel treatment strategies.

How Will the Muscle Wasting Disorders Market Size Evolve and Grow by 2029?
Anticipation is high for substantial expansion within the muscle wasting disorders marketplace over the ensuing years, projecting a valuation of $29.52 billion by 2029, propelled by a compound annual growth rate (CAGR) reaching 14.0%. This forward growth trajectory is largely credited to intensifying regulatory endorsement, proactive patient advocacy efforts, enhancements in medical infrastructure provisioning, the worldwide spread of clinical studies, and the implementation of individualized treatment strategies. Furthermore, significant shifts expected during this projection time frame encompass wider utilization of telemedicine, progress in diagnostic technologies, novel product development, increased tactical alliances and cooperative ventures, breakthroughs in medicinal treatments, deeper investigation into the underlying molecular processes, and heightened biopharmaceutical ingenuity.

View the full report here:
https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report

What Drivers Are Propelling the Growth of Muscle Wasting Disorders Market Forward?
The increasing prevalence of inactivity in daily routines is anticipated to fuel the expansion of the market for muscle wasting disorders in the foreseeable future; this inactive way of living, characterized by minimal to no physical activity or exercise, negatively affects muscle performance, resulting in diminished strength and stamina, thereby contributing to muscle deterioration conditions and complicating the ability of individuals to preserve their muscle bulk and functionality. To illustrate this trend, data from the World Health Organization, an international body headquartered in Switzerland, indicated that in the year 2022, more than 80 percent of teenagers, alongside 27 percent of the adult population, failed to meet the physical activity guidelines set forth by the WHO, consequently positioning the growing trend of sedentary living as a key driver for the advancement of the muscle wasting disorders market segment.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13706&type=smp

Which Emerging Trends Are Transforming the Muscle Wasting Disorders Market in 2025?
Major companies operating in the muscle wasting disorders market are focusing on developing advanced treatments, such as novel gene therapies, to improve care for patients affected by these conditions. Novel gene therapy involves medical techniques that create therapeutic effects by modifying gene expression or altering the biological characteristics of living cells. For example, in June 2023, Sarepta Therapeutics, a US-based biotechnology firm, launched Elevidys, the first gene therapy approved by the U.S. Food and Drug Administration (FDA) for treating Duchenne muscular dystrophy (DMD) in children aged 4 to 5 years. Elevidys is a recombinant gene therapy that introduces a gene responsible for producing a shortened form of the dystrophin protein found in healthy muscle cells. The treatment is administered as a single intravenous infusion.

What Are the Key Segments in the Muscle Wasting Disorders Market?
The muscle wasting disordersmarket covered in this report is segmented -

1) By Treatment Type: Medications; Physical Therapy; Nutritional Therapy; Surgery; Gene Therapy; Other Treatment Types
2) By Disorder Type: Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS); Other Disorder Types
3) By End-User: Hospitals; Rehab Centers; Specialty Clinics; Other End-Users

Subsegments:
1) By Medications: Anabolic Steroids; Hormonal Treatments; Anti-Inflammatory Drugs; Immunomodulatory Agents
2) By Physical Therapy: Resistance Training; Stretching Exercises; Aerobic Conditioning; Rehabilitation Programs
3) By Nutritional Therapy: Protein Supplements; Nutritional Counseling; Dietary Modifications; Micronutrient Supplements
4) By Surgery: Surgical Interventions For Muscle Repair; Orthopedic Surgeries; Procedures For Underlying Conditions
5) By Gene Therapy: Gene Replacement Therapy; CRISPR-Based Approaches; RNA Interference Techniques
6) By Other Treatment Types: Complementary Therapies; Psychological Support; Assistive Devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13706&type=smp

Who Are the Key Players Shaping the Muscle Wasting Disorders Market's Competitive Landscape?
Major companies operating in the muscle wasting disorders market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.), Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Axogen, Inc., FibroGen Inc., Cytokinetics Incorporated, Italfarmaco S.p.A., Scholar Rock, Bellerophon Therapeutics, Akashi Therapeutics, aTyr Pharma, Metabolic Solutions Development Company, Synaptogenix, MyoKardia, Inc., MyoTherix Inc.

What Geographic Markets Are Powering Growth in the Muscle Wasting Disorders Market?
North America was the largest region in the muscle wasting disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle wasting disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13706

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.